These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 25440006)

  • 1. AT-1001: a high-affinity α3β4 nAChR ligand with novel nicotine-suppressive pharmacology.
    Cippitelli A; Wu J; Gaiolini KA; Mercatelli D; Schoch J; Gorman M; Ramirez A; Ciccocioppo R; Khroyan TV; Yasuda D; Zaveri NT; Pascual C; Xie XS; Toll L
    Br J Pharmacol; 2015 Apr; 172(7):1834-45. PubMed ID: 25440006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AT-1001: a high affinity and selective α3β4 nicotinic acetylcholine receptor antagonist blocks nicotine self-administration in rats.
    Toll L; Zaveri NT; Polgar WE; Jiang F; Khroyan TV; Zhou W; Xie XS; Stauber GB; Costello MR; Leslie FM
    Neuropsychopharmacology; 2012 May; 37(6):1367-76. PubMed ID: 22278092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential regulation of alcohol taking and seeking by antagonism at α4β2 and α3β4 nAChRs.
    Cippitelli A; Brunori G; Schoch J; Armishaw CJ; Wu J; Zaveri NT; Giulianotti MA; Welmaker GS; Toll L
    Psychopharmacology (Berl); 2018 Jun; 235(6):1745-1757. PubMed ID: 29572652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Varenicline blocks β2*-nAChR-mediated response and activates β4*-nAChR-mediated responses in mice in vivo.
    Ortiz NC; O'Neill HC; Marks MJ; Grady SR
    Nicotine Tob Res; 2012 Jun; 14(6):711-9. PubMed ID: 22241831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The contribution of agonist and antagonist activities of α4β2* nAChR ligands to smoking cessation efficacy: a quantitative analysis of literature data.
    Rollema H; Hurst RS
    Psychopharmacology (Berl); 2018 Sep; 235(9):2479-2505. PubMed ID: 29980822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The α3β4 nAChR partial agonist AT-1001 attenuates stress-induced reinstatement of nicotine seeking in a rat model of relapse and induces minimal withdrawal in dependent rats.
    Yuan M; Malagon AM; Yasuda D; Belluzzi JD; Leslie FM; Zaveri NT
    Behav Brain Res; 2017 Aug; 333():251-257. PubMed ID: 28693859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of the nicotinic agonist varenicline, nicotinic antagonist r-bPiDI, and DAT inhibitor (R)-modafinil on co-use of ethanol and nicotine in female P rats.
    Maggio SE; Saunders MA; Baxter TA; Nixon K; Prendergast MA; Zheng G; Crooks P; Dwoskin LP; Slack RD; Newman AH; Bell RL; Bardo MT
    Psychopharmacology (Berl); 2018 May; 235(5):1439-1453. PubMed ID: 29455292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Partial agonists of the α3β4* neuronal nicotinic acetylcholine receptor reduce ethanol consumption and seeking in rats.
    Chatterjee S; Steensland P; Simms JA; Holgate J; Coe JW; Hurst RS; Shaffer CL; Lowe J; Rollema H; Bartlett SE
    Neuropsychopharmacology; 2011 Feb; 36(3):603-15. PubMed ID: 21048701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological stress is required for the anti-alcohol effect of the α3β4* nAChR partial agonist AT-1001.
    Cippitelli A; Brunori G; Gaiolini KA; Zaveri NT; Toll L
    Neuropharmacology; 2015 Jun; 93():229-36. PubMed ID: 25689019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CC4, a dimer of cytisine, is a selective partial agonist at α4β2/α6β2 nAChR with improved selectivity for tobacco smoking cessation.
    Sala M; Braida D; Pucci L; Manfredi I; Marks MJ; Wageman CR; Grady SR; Loi B; Fucile S; Fasoli F; Zoli M; Tasso B; Sparatore F; Clementi F; Gotti C
    Br J Pharmacol; 2013 Feb; 168(4):835-49. PubMed ID: 22957729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional interactions of varenicline and nicotine with nAChR subtypes implicated in cardiovascular control.
    Rollema H; Russ C; Lee TC; Hurst RS; Bertrand D
    Nicotine Tob Res; 2014 Jun; 16(6):733-42. PubMed ID: 24406270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AT-1001 Is a Partial Agonist with High Affinity and Selectivity at Human and Rat α3β4 Nicotinic Cholinergic Receptors.
    Tuan EW; Horti AG; Olson TT; Gao Y; Stockmeier CA; Al-Muhtasib N; Bowman Dalley C; Lewin AE; Wolfe BB; Sahibzada N; Xiao Y; Kellar KJ
    Mol Pharmacol; 2015 Oct; 88(4):640-9. PubMed ID: 26162864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences in mechanisms underlying reinstatement of cigarette smoke extract- and nicotine-seeking behavior in rats.
    Cross SJ; Reynaga DD; Cano M; Belluzzi JD; Zaveri NT; Leslie FM
    Neuropharmacology; 2020 Jan; 162():107846. PubMed ID: 31704271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. α-Conotoxin TxID and [S9K]TxID, α3β4 nAChR Antagonists, Attenuate Expression and Reinstatement of Nicotine-Induced Conditioned Place Preference in Mice.
    Li X; You S; Xiong J; Qiao Y; Yu J; Zhangsun D; Luo S
    Mar Drugs; 2020 Dec; 18(12):. PubMed ID: 33339145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New insights on the effects of varenicline on nicotine reward, withdrawal and hyperalgesia in mice.
    Bagdas D; Alkhlaif Y; Jackson A; Carroll FI; Ditre JW; Damaj MI
    Neuropharmacology; 2018 Aug; 138():72-79. PubMed ID: 29860196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The high-affinity nAChR partial agonists varenicline and sazetidine-A exhibit reinforcing properties in rats.
    Paterson NE; Min W; Hackett A; Lowe D; Hanania T; Caldarone B; Ghavami A
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Dec; 34(8):1455-64. PubMed ID: 20708056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nicotinic acetylcholine receptors containing the α4 subunit are critical for the nicotine-induced reduction of acute voluntary ethanol consumption.
    Hendrickson LM; Gardner P; Tapper AR
    Channels (Austin); 2011; 5(2):124-7. PubMed ID: 21239887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Highly Selective and Potent α4β2 nAChR Antagonist Inhibits Nicotine Self-Administration and Reinstatement in Rats.
    Wu J; Cippitelli A; Zhang Y; Debevec G; Schoch J; Ozawa A; Yu Y; Liu H; Chen W; Houghten RA; Welmaker GS; Giulianotti MA; Toll L
    J Med Chem; 2017 Dec; 60(24):10092-10104. PubMed ID: 29178785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SSR591813, a novel selective and partial alpha4beta2 nicotinic receptor agonist with potential as an aid to smoking cessation.
    Cohen C; Bergis OE; Galli F; Lochead AW; Jegham S; Biton B; Leonardon J; Avenet P; Sgard F; Besnard F; Graham D; Coste A; Oblin A; Curet O; Voltz C; Gardes A; Caille D; Perrault G; George P; Soubrie P; Scatton B
    J Pharmacol Exp Ther; 2003 Jul; 306(1):407-20. PubMed ID: 12682217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid.
    Rollema H; Chambers LK; Coe JW; Glowa J; Hurst RS; Lebel LA; Lu Y; Mansbach RS; Mather RJ; Rovetti CC; Sands SB; Schaeffer E; Schulz DW; Tingley FD; Williams KE
    Neuropharmacology; 2007 Mar; 52(3):985-94. PubMed ID: 17157884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.